Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.

Grail, a US-based medical diagnostics technology developer that has raised more than $1.9bn in funding from investors including a range of corporates, filed for a $100m initial public offering yesterday. Morgan Stanley, Goldman Sachs and BofA Securities are lead bookrunners for the IPO while Cowen and Evercore ISI are also bookrunners. The $100m represents a…

The rest of this content is only accessible to Subscribers.

This content is only accessible to subscribers. If you are a subscriber, please sign in. Otherwise, if you would like to try before you buy and haven't previously taken out a free trial, you can do so below. You can also see details on subscriptions by clicking the Subscription Options button.